奥马珠单抗 3 年长疗程治疗重度激素依赖型 过敏性哮喘的疗效及安全性.

Objective To investigate the clinical efficacy and safety of long-term application of omalizumab in the treatment of severe hormone dependent allergic asthma. Methods Seven cases of severe hormone dependent allergic asthma treated with omalizumab for 3 years were collected from Department of Respiratory Medicine, Zhongshan Hospital, Fudan University. Results of oral corticosteroid (OCS) doses, acute attack frequency, asthma control test (ACT), asthma quality of life (AQLQ), forced vital capacity (FVC), forced expiratory volume in first second (FEV1) and percentage to predicted value (FEV1% pred), and forced expiratory volume in the first second over forced vital capacity (FEV1/FVC) before and after omalizumab treatment were compared in this study. Results After treatment of omalizumab for 3 years, the oral prednisone doses of the 7 cases decreased from 15.0 (15.0-22.5) mg/d to 2.5（0-10.0) mg/d (P<0.01), and acute attack frequency decreased from 6 (4-7) per year to 0（0-1) per year (P<0.01). The ACT scores of 7 patients with severe asthma increased from 18.0 (13.0-20.0) to 22.0 (18.0-24.0), and AQLQ scores increased from (4.5±1.4) to (5.1±1.1). After treatment of omalizumab for 3 years, FEV1 increased from baseline (2.2±1.0) L to (2.5±1.3) L, FEV1% pred increased from baseline 74.4%±29.2% to 77.5%±27.2%, FEV1/FVC (%) increased from baseline 68.4%±11.9% to 69.8%±16.3%. One case had swelling at the injection site, and the rest had no obvious adverse reactions during the long-term treatment with omalizumab. Conclusion Long-term application of omalizumab in the treatment of severe hormone dependent allergic asthma could effectively reduce oral prednisone doses and acute attack frequency, control asthma symptoms and improve pulmonary ventilation function of patients and also has good safety. [ABSTRACT FROM AUTHOR]